Quarterly report [Sections 13 or 15(d)]

License Agreements (Details)

v3.26.3
License Agreements (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2026
Dec. 31, 2012
Jul. 31, 2026
Apr. 21, 2026
License Agreements          
Revenue under the PRIDCor license agreement $ 100,000 $ 100,000      
Cost of goods sold 88,104 88,104      
PRIDCor Therapeutics, LLC License Agreement          
License Agreements          
Percentage of Series A financing receivable         10.00%
Percentage of financing receivable except Series A financing         9.00%
Revenue remaining performance obligation 0 0      
Revenue under the PRIDCor license agreement 100,000 100,000      
License agreement amount       $ 1,000,000  
Cash payments 87,750 87,750      
Cash payments for processing fees $ 354 354      
PRIDCor Therapeutics, LLC License Agreement | Maximum          
License Agreements          
Percentage of royalty on net sales         15.00%
Amount of exit consideration         $ 100,000,000
Agreement          
License Agreements          
Percentage of non-voting membership interest     10.00%    
License agreement expiration period     25 years    
Serpin License Agreement | License for SP16 Development          
License Agreements          
Direct transaction costs   121,000      
Total consideration paid   12,030,667      
Serpin License Agreement | License for SP16 Development | Common Stock          
License Agreements          
Total consideration paid   2,108,828      
Serpin License Agreement | License for SP16 Development | Series A-2 Non-Voting Convertible Preferred Stock          
License Agreements          
Total consideration paid   $ 9,800,839